Orthopaedic treatment of patients using the device to determine and fix the central bite

A large number of errors, which often occur in prosthodontics in prosthetics patients with non-fixed bite, mainly related to the quality of the determination and the central Bite. Violation of the natural position of the mandible leads to a pathological condition in a patient from the TMJ and masticatory muscles goal of our work was the development and application of new devices for the measurement and recording centric relation jaw. Proper identification and recording centric relation jaw can improve the quality of prosthetic patients in terms of functional value of dentures and accelerate the process of adaptation of patients to removable dentures.Большое количество ошибок, которые часто встречаются в практике ортопедической стоматологии при протезировании больных с нефиксированным прикусом, связаны в основном с качеством определения и фиксации центрального соотношения челюстей. Нарушение естественного положения нижней челюсти приводит к возникновению патологических состояний у пациента со стороны височно-нижнечелюстного сустава и жевательной мускулатуры. Целью нашей работы явилось разработка и применение нового устройства для определения и фиксации центрального соотношения челюстей. Правильное определение и фиксация центрального соотношения челюстей позволяет повысить качество протезирования пациентов с точки зрения функциональной ценности съемных протезов и ускорить процесс адаптации больных к съемным протезам

Epidemiological Surveillance over HIV-infection Including Patients Co-infected with HIV and Viral Hepatitis in the Far Eastern Federal District

Relevance. HIV-infection continues to be one of the unsolved issues of modern healthcare. In the Russian Federation, an annual increase in the number HIV-infected people including co-infected with HIV and viral hepatitis is registered. This is associated with common transmission mechanisms of the diseases. Objective: to conduct a retrospective analysis of the main HIV-infection epidemiological indices that included prevalence of viral hepatitis B and C among people living with HIV in the Far Eastern Federal district during years 2006–2018. Materials and methods: the conducted retrospective epidemiological analysis was based on evaluation of materials provided by AIDS prevention and control regional centers as well as in the official statistical data form № 61 «Data on HIVinfected contingents». Analysis of the obtained data included parametric and nonparametric statistics. Results. A deterioration of the epidemic situation concerning HIV-infection with and without viral hepatitis B and C was registered in the Far Eastern Federal district. The fraction of HIV-positive people aged 40 years and older increased up to 24.68 ± 0.26% in 2018. Feminization of HIV-infected population was observed. The fraction of HIV-positive women increased from 32.30 ± 0.50 % in 2006 to 36.82 ± 0.29% in 2018. The fraction of sexual transmission mechanism of the HIV has increased during the observed period of time and totaled 40.60 ± 0.30% in 2018. This fact plays a significant part in the spread of HIV in the Far Eastern Federal district. Conclusion. The revealed tendencies indicate a necessity of changing the preventive measures strategy against HIV

Prevalence and molecular-genetic characteristics of hepatitis B virus in HIV-positive individuals at the Far Eastern Federal District

Current study was aimed at investigating prevalence of overt and occult hepatitis B infection in HIV-positive individuals as well as molecular-epidemiological characteristics of the circulating hepatitis B virus (HBV) strains in the Far Eastern Federal District (FEFD). A total number of 297 blood serum/plasma samples obtained from HIV-positive patients residing in the FEFD were enrolled in the study. The first control group included 351 blood serum/plasma samples of general population without indication on HIV and HBV-infection that underwent laboratory check up at the Centers for AIDS Prevention and Control. After evaluating the group of HIV-positive patients 20 HIV-HBV positive samples were selected for further detailed analysis. The second control group included 43 patients with chronic hepatitis B. All groups were age and gender-matched. The research included serological and molecular-genetic (real-time PCR, positive for HBV DNA samples underwent clonal sequencing of PCR-amplified HBV P/S gene) assessment of the biological material followed by a phylogenetic analysis of the HBV sequences. Our research revealed that HIV-positive patients are exposed to a higher risk of HBV infection compared to general population enrolled in the study, which is evident from the prevalence of anti-HBcAg antibodies in the groups examined. HIV-positive vs. first control group was positive for anti-HBcAg antibodies at higher rate (35.02%, CI 95: 29.59–40.45% versus 22.22%, CI 95: 17.87–26.57%, p = 0.0003). Abundance of ongoing HBV-infection markers was also higher in HIV-positive individuals compared to general population (6.73%, CI 95: 3.88–9.58% versus 0.85%, CI 95: 0–1.81%, p = 0.0001, respectively). Should be noted, that HBsAg-negative HBV infection in HIV-positive patient cohort comprised 1.01% (CI 95: 0–2.15%) whereas in general population this index was as low as 0.28% (CI 95: 0–0.84%). Virus hepatitis С and D were revealed at higher rate in HIV-positive individuals compared to patients with HIV-negative chronic HBV infection (p = 5.84 × 10–7  and p = 0.000001 respectively). HCV and HDV prevalence rates comprised 50.0% (CI 95: 27.46–77.46%) and 40.0% (CI 95: 17.97–62.03%) in HIV-positive patients. Similar indices in control group were 4.65% (CI 95: 0–10.94%) and 4.65% (CI 95: 0–10.94%), respectively. The phylogenetic analysis of the six isolated HBV sequences showed that the five samples belonged to genotype D, with dominant subtype D2 (verified in 4 cases). Further, HBV genotype С was detected only in one case. The obtained data indicate a necessity for further in-depth diagnostic examination of viral hepatitis in HIV-positive patients to lower a risk of developing life-threatening complications as well as preventing hepatitis spread in human population

Efficacy and tolerability of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer: results of a multicenter observational study in the Russian Federation

Background. The implementation of tyrosine kinase inhibitors into clinical practice improved treatment outcomes in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC). Lenvatinib is recommended as a first-line drug for these patients. The study objective is to analyze clinical experience with lenvatinib in patients with RR-DTC in the Russian Federation. Materials and methods. The data from 18 clinical sites in Russia was analyzed for the period December 2015 and September 2019. Seventyseven patients with histologically verified DTC, proven resistance to radioactive iodine therapy, and tumor progression (according to the Response Evaluation Criteria In Solid Tumors 1.1 criteria) were included in the study. Results.Median progression-free survival in patients included into analysis (n = 72) was 26.1 months. In patients who responded to therapy (including those with partial and complete response), median progression-free survival reached 36.2 months, which is higher than that reported in the updated results of the SELECT study (33.1 months). Lenvatinib-associated adverse events (AEs) were observed in 87 % of patients. Severe AEs were registered in 18.2 % of participants. In 6.5 % of cases, AEs lead to lenvatinib cessation; in 74 % of cases, AEs required dose reduction.Conclusion. Our findings suggest high efficacy and good tolerability of lenvatinib in patients with RR-DTC in routine clinical practice in the Russian Federation